News

November 1, 2019November 11, 2019

Copiktra May Be Treatment Option for Advanced Marginal Zone Lymphoma, Trial Data Show

News

Copiktra (duvelisib), developed by Verastem Oncology, may be an effective and reasonably safe treatment option for people with marginal zone lymphoma who failed to respond to prior therapies including rituximab, Phase 2 ... Read more

October 31, 2019

Cirmtuzumab-Imbruvica Combo Trial Opens New Expansion Part for Mantle Cell Lymphoma

News

A Phase 1/2 trial assessing Oncternal Therapeutics‘ cirmtuzumab plus Imbruvica (ibrutinib) for the treatment of B-cell cancers is opening a Phase 1b extension part to continue studying the combination in ... Read more

October 29, 2019

Copiktra Superior to Arzerra for CLL/SLL Patients with Prior Therapies, Data Suggest

News

Treatment with Copiktra (duvelisib) doubles response rates compared with Arzerra (ofatumumab), and significantly extends the time until disease progression or death in people with chronic lymphocytic leukemia (CLL) or ... Read more

October 25, 2019

Durable Responses Seen to ME-401 in Advanced Follicular Lymphoma and CLL/SLL Patients in Ongoing Trial

News

MEI Pharma’s experimental compound ME-401 reduced tumor burden in 78% of patients with relapsed or refractory follicular lymphoma and in 89% of those with relapsed or refractory chronic lymphocytic leukemia ... Read more

October 24, 2019October 24, 2019

Follicular Lymphoma Patients Being Recruited for Phase 2 Trial of Aliqopa-Rituximab Combo

News

A Phase 2 clinical trial is recruiting patients with untreated follicular lymphoma — the most common type of non-Hodgkin’s lymphoma — to study a combination of Aliqopa (copanlisib) and rituximab. The ... Read more

October 22, 2019

Phase 2 Trial Testing Darinaparsin Completes Enrollment of Asian Patients with Relapsed or Refractory PTCL

News

A Phase 2 clinical trial assessing Solasia Pharma’s lead candidate darinaparsin as a treatment for relapsed or refractory peripheral T-cell lymphoma (PTCL) in Asian patients has reached its target ... Read more

October 18, 2019

HIV-positive, Non-Hodgkin’s Lymphoma Patients Should Receive Chemotherapy Along with Antiretrovirals Therapy, Retrospective Study Says

News

People with non-Hodgkin’s lymphoma who are HIV-positive and have not received antiretroviral therapy — a treatment that stops HIV from replicating — have similar outcomes on standard R-CHOP chemotherapy, ... Read more

October 17, 2019

HealthWell Foundation Offers Treatment Payment Assistance for Mantle Cell Lymphoma

News

To allow patients to focus on treatment and not cost, the HealthWell Foundation is offering copayment and insurance premium assistance to people with mantle cell lymphoma (MCL) who are ... Read more

October 15, 2019

Rituxan Biosimilar IBI301 Shows Similar Safety, Efficacy to Original in B-cell Lymphomas, Trials Show

News

IBI301, a biosimilar to Rituxan (rituximab), has a similar response rate to the original compound in people with B-cell lymphomas, and behaves similarly inside the body, preliminary results of two ... Read more

October 10, 2019

Copiktra Receives FDA’s Orphan Drug Status for T-cell Lymphoma Treatment

News

The small molecule inhibitor Copiktra (duvelisib) has been given orphan status by the U.S. Food and Drug Administration (FDA) for the treatment of T-cell lymphoma, the therapy’s developer, Verastem ... Read more

Pin It on Pinterest